LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands. Show more
Location: Yalelaan 62, Utrecht, 3584 CM, Netherlands | Website: https://www.lavatherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
41.3M
52 Wk Range
$0.85 - $2.09
Previous Close
$1.57
Open
$1.56
Volume
33,372
Day Range
$1.54 - $1.57
Enterprise Value
-14.87M
Cash
56.17M
Avg Qtr Burn
-8.97M
Insider Ownership
32.69%
Institutional Own.
36.39%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PF-08046052 (formerly LAVA-1223) Details Cancer, Solid tumor/s | Phase 1 Update | |
LAVA-1266 Details Cancer, Hematologic malignancies, Acute myeloid leukemia, Myelodysplastic syndrome | Failed Discontinued | |
LAVA-1207 Details Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer, Prostate disease | Failed Discontinued | |
LAVA-051 ( gamma-delta bsTCE targeting CD1d-expressing tumors) Details Solid tumor/s, Cancer, Chronic lymphocytic leukemia, Acute myeloid leukemia, Multiple myeloma | Failed Discontinued |